Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene TP53
Variant Y220C
Impact List missense
Protein Effect loss of function
Gene Variant Descriptions TP53 Y220C is a hotspot mutation that lies within the DNA-binding domain (PMID: 17401432). Y220C results in decreased DNA binding, reduced Tp53 transcriptional activity, leads to resistance to apoptosis and failure of G1 arrest in cell culture (PMID: 16861262, PMID: 23630318, PMID: 31395785).
Associated Drug Resistance
Category Variants Paths

TP53 mutant TP53 exon6 TP53 Y220C

TP53 mutant TP53 inact mut TP53 Y220C

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_000546.6
gDNA chr17:g.7674872T>C
cDNA c.659A>G
Protein p.Y220C
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001407264.1 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_001126114.3 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_000546 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_001126113.3 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_001126113.2 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_000546.6 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_001126112.2 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_001407262.1 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_001126112.3 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_001126114 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_001126114.2 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_001126112 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_001126113 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_001407266.1 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_000546.5 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_001407270.1 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38
NM_001407268.1 chr17:g.7674872T>C c.659A>G p.Y220C RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
TP53 Y220C lung non-small cell carcinoma resistant Seliciclib Preclinical - Cell culture Actionable In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 Y220C were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161). 22862161
TP53 Y220C hepatocellular carcinoma sensitive CP-31398 Preclinical - Cell culture Actionable In a preclinical study, treatment with CP-31398 resulted in decreased proliferation, increased apoptosis, and cell-cycle arrest in a hepatocellular carcinoma cell line harboring TP53 Y220C in culture (PMID: 26250460). 26250460
TP53 Y220C hepatocellular carcinoma sensitive SLMP53-2 Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with SLMP53-2 induced cell-cycle arrest and apoptosis and inhibited growth, and resulted in restored Tp53 transcriptional activity in a hepatocellular carcinoma cell line harboring TP53 Y220C in culture, and inhibited tumor growth in xenograft models (PMID: 31405179). 31405179
TP53 Y220C breast ductal carcinoma sensitive SLMP53-2 Preclinical - Cell culture Actionable In a preclinical study, SLMP53-2 treatment inhibited growth of a breast ductal carcinoma cell line harboring TP53 Y220C and resulted in increased expression of the Tp53 targets MDM2, p21, and KILLER and decreased expression of Survivin and VEGF in culture (PMID: 31405179). 31405179
TP53 Y220C lung non-small cell carcinoma sensitive SLMP53-2 Preclinical - Cell culture Actionable In a preclinical study, SLMP53-2 inhibited growth of a non-small cell lung carcinoma cell line expressing TP53 Y220C in culture (PMID: 31405179). 31405179
TP53 Y220C hepatocellular carcinoma sensitive SLMP53-2 + Sorafenib Preclinical - Cell culture Actionable In a preclinical study, treatment with the combination of SLMP53-2 and Nexavar (sorafenib) inhibited growth of a hepatocellular carcinoma cell line harboring TP53 Y220C in culture, and resulted in increased inhibition compared to Nexavar (sorafenib) alone (PMID: 31405179). 31405179
TP53 Y220C breast cancer predicted - sensitive PC14586 Case Reports/Case Series Actionable In a Phase I trial, PC14586 treatment resulted in a partial response in a patient with breast cancer harboring TP53 Y220C (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3003); NCT04585750). detail...
TP53 Y220C lung small cell carcinoma predicted - sensitive PC14586 Case Reports/Case Series Actionable In a Phase I trial, PC14586 treatment resulted in a partial response in a patient with small cell lung cancer harboring TP53 Y220C (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3003); NCT04585750). detail...
TP53 Y220C colorectal cancer predicted - sensitive PC14586 Case Reports/Case Series Actionable In a Phase I trial, PC14586 treatment resulted in an unconfirmed partial response in a patient with colorectal cancer harboring TP53 Y220C (J Clin Oncol 40,no. 16_suppl (June 01, 2022) 3003); NCT04585750). detail...
TP53 Y220C prostate cancer predicted - sensitive PC14586 Case Reports/Case Series Actionable In a Phase I trial, PC14586 treatment resulted in unconfirmed partial responses in two patients with prostate cancer harboring TP53 Y220C (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3003); NCT04585750). detail...
TP53 Y220C stomach cancer predicted - sensitive PC14586 Preclinical - Cell line xenograft Actionable In a preclinical study, PC14586 treatment reactivated Tp53 function, resulted in 80% tumor regression after 3 weeks in cell line xenograft models of gastric cancer harboring TP53 Y220C (AACR Annual Meeting Apr 2021, Session MS.LBA01, Abstract # LB006). detail...
TP53 Y220C Advanced Solid Tumor predicted - sensitive PC14586 Phase I Actionable In a Phase I trial, PC14586 treatment demonstrated safety and preliminary efficacy in patients with advanced solid tumors harboring TP53 Y220C, and resulted in 5 partial responses amongst 21 evaluable patients including confirmed partial responses in one small cell lung cancer and one breast cancer patient, and unconfirmed partial responses in one colorectal cancer and two prostate cancer patients (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3003); NCT04585750). detail...
TP53 Y220C Advanced Solid Tumor predicted - sensitive PC14586 Preclinical - Cell line xenograft Actionable In a preclinical study, PC14586 treatment reactivated Tp53 function and resulted in cell cycle arrest in cancer cell lines harboring TP53 Y220C in culture, and led to complete cure in 80% of syngeneic xenograft models (AACR Annual Meeting Apr 2021, Session MS.LBA01, Abstract # LB006). detail...